González-Álvarez Isabel, Sánchez-Dengra Bárbara, Rodriguez-Galvez Raquel, Ruiz-Picazo Alejandro, González-Álvarez Marta, García-Arieta Alfredo, Bermejo Marival
Engineering: Pharmacokinetics and Pharmaceutical Technology Area, Miguel Hernandez University, 03550 San Juan de Alicante, Spain.
Service of Pharmacokinetics and Generic Medicines, Division of Pharmacology and Clinical Evaluation, Department of Human Use Medicines, Spanish Agency for Medicines and Health Care Products, 28022 Madrid, Spain.
Pharmaceutics. 2022 Nov 23;14(12):2565. doi: 10.3390/pharmaceutics14122565.
Some years ago, excipients were considered inert substances irrelevant in the absorption process. However, years of study have demonstrated that this belief is not always true. In this study, the reasons for a bioequivalence failure between two formulations of silodosin are investigated. Silodosin is a class III drug according to the Biopharmaceutics Classification System, which has been experimentally proven by means of solubility and permeability experiments. Dissolution tests have been performed to identify conditions concordant with the non-bioequivalent result obtained from the human bioequivalence study and it has been observed that paddles at 50 rpm are able to detect inconsistent differences between formulations at pH 4.5 and pH 6.8 (which baskets at 100 rpm are not able to do), whereas the GIS detects differences at the acidic pH of the stomach. It has also been observed that the differences in excipients between products did not affect the disintegration process, but disintegrants did alter the permeability of silodosin through the gastrointestinal barrier. Crospovidone and povidone, both derivatives of PVP, are used as disintegrants in the test product, instead of the pregelatinized corn starch used in the reference product. Permeability experiments show that PVP increases the absorption of silodosin-an increase that would explain the greater C observed for the test product in the bioequivalence study.
几年前,辅料被认为是在吸收过程中无关紧要的惰性物质。然而,多年的研究表明,这种观点并非总是正确的。在本研究中,对两种西洛多辛制剂之间生物等效性失败的原因进行了调查。根据生物药剂学分类系统,西洛多辛属于III类药物,这已通过溶解度和渗透性实验得到实验证明。已进行溶出度试验,以确定与人体生物等效性研究中获得的非生物等效结果相一致的条件,并且观察到,在pH 4.5和pH 6.8时,50转/分钟的桨法能够检测到制剂之间不一致的差异(100转/分钟的篮法无法做到),而胃肠道模拟器(GIS)能检测到胃酸性pH值下的差异。还观察到,产品之间辅料的差异不影响崩解过程,但崩解剂确实改变了西洛多辛通过胃肠道屏障的渗透性。交联聚维酮和聚维酮均为PVP的衍生物,在受试产品中用作崩解剂,而参比产品中使用的是预胶化玉米淀粉。渗透性实验表明,PVP增加了西洛多辛的吸收,这种增加可以解释在生物等效性研究中受试产品观察到的更高的Cmax。